newsfilter
← Latest News
PR Newswire·

Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

  • Leonard Mazur, Chairman & CEO of Citius Pharmaceuticals, Inc., will attend the Jefferies London Healthcare Conference from November 16–19, 2026, at Waldorf Hilton & ME Hotels in London.
  • Mazur will hold one-on-one business development meetings to discuss the Company's business & recent developments, including the commercialization of LYMPHIR by majority-owned subsidiary Citius Oncology, Inc.
  • LYMPHIR was launched by Citius Oncology in December 2025 for adults with relapsed or refractory Stage I–III CTCL who had prior systemic therapy.
  • Citius Pharmaceuticals owns approximately 71% of Citius Oncology & maintains a late-stage pipeline including Mino-Lok & CITI-002 (Halo-Lido).
  • Mino-Lok successfully met primary & secondary endpoints in its Phase 3 trial in 2023, while Citius Pharma is engaging with the FDA regarding next steps for Mino-Lok & Halo-Lido.
  • Citius Oncology estimates the initial market for LYMPHIR exceeds $400 million & is supported by orphan drug designation & intellectual property protections.
  • Investor & media contacts are listed for further inquiries regarding the Company & its upcoming conference participation.
Company
Citius Pharmaceuticals, Inc.
Keywords
Citius Pharmaceuticals, Inc.